Cancer cells exploit an orphan RNA to drive metastatic progression. Read more about Cancer cells exploit an orphan RNA to drive metastatic progression.
A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Read more about A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments.
A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Read more about A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Read more about CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade.
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Read more about Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Understanding the tumor immune microenvironment (TIME) for effective therapy. Read more about Understanding the tumor immune microenvironment (TIME) for effective therapy.
Corrigendum: Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors. Read more about Corrigendum: Genome-wide CRISPR screens reveal a Wnt-FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors.
Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy? Read more about Corrigendum: Is autoimmunity the Achilles' heel of cancer immunotherapy?
Is autoimmunity the Achilles' heel of cancer immunotherapy? Read more about Is autoimmunity the Achilles' heel of cancer immunotherapy?
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Read more about A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress.
